{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:18:23Z","timestamp":1763727503827,"version":"3.41.2"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Neurosci."],"DOI":"10.3389\/fnmol.2019.00094","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T05:48:37Z","timestamp":1556084917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets"],"prefix":"10.3389","volume":"12","author":[{"given":"Mar\u00eda","family":"G\u00f3mez-Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Rodr\u00edguez-Cueto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Luna-Pi\u00f1el","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariluz","family":"Hern\u00e1ndez-G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/hmg\/ddq111","article-title":"Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?","volume":"19","author":"Alves","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.pnpbp.2015.03.008","article-title":"Cannabinoids to treat spinal cord injury.","volume":"64","author":"Arevalo-Martin","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bcp.2018.08.016","article-title":"Cannabinoid pharmacology\/therapeutics in chronic degenerative disorders affecting the central nervous system.","volume":"157","author":"Aymerich","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1073\/pnas.1217121110","article-title":"ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC.","volume":"110","author":"Blankman","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-00696-y","article-title":"Genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias.","author":"Buijsen","year":"2019","journal-title":"Neurotherapeutics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/2053-8871-1-4","article-title":"From mice to men: lessons from mutant ataxic mice.","volume":"1","author":"Cendelin","year":"2014","journal-title":"Cerebellum Ataxias"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/humu.22437","article-title":"Two novel mutations in ABHD12: expansion of the mutation spectrum in PHARC and assessment of their functional effects.","volume":"34","author":"Chen","year":"2013","journal-title":"Hum. Mutat."},{"key":"B8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.nbd.2010.10.019","article-title":"HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.","volume":"41","author":"Chou","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.biomaterials.2015.12.021","article-title":"Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype.","volume":"82","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"Biomaterials"},{"key":"B10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00213-011-2387-0","article-title":"Cannabinoid-induced motor incoordination through the cerebellar CB1 receptor in mice.","volume":"69","author":"DeSanty","year":"2001","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrn3876","article-title":"Endocannabinoid signalling and the deteriorating brain.","volume":"16","author":"Di Marzo","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(10)70183-6","article-title":"Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond.","volume":"9","author":"Durr","year":"2010","journal-title":"Lancet Neurol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14382","article-title":"The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes.","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s13311-015-0381-7","article-title":"Cannabinoids in neurodegenerative disorders and stroke\/brain trauma: from preclinical models to clinical applications.","volume":"12","author":"Fern\u00e1ndez-Ruiz","year":"2015","journal-title":"Neurotherapeutics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.tips.2006.11.001","article-title":"Cannabinoid CB2 receptor: a new target for controlling neural cell survival?","volume":"28","author":"Fern\u00e1ndez-Ruiz","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ajhg.2010.08.002","article-title":"Mutations in ABHD12 cause the neurodegenerative disease PHARC: an inborn error of endocannabinoid metabolism.","volume":"87","author":"Fiskerstrand","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/b978-0-444-51892-7.00005-x","article-title":"Neuropathology of degenerative ataxias.","volume":"103","author":"Fratkin","year":"2012","journal-title":"Handb. Clin. Neurol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14369","article-title":"Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells.","author":"Garc\u00eda-Arencibia","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-71779-1_1","article-title":"Clinical features of huntington\u2019s disease.","volume":"1049","author":"Ghosh","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13311-012-0117-x","article-title":"Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease).","volume":"9","author":"Gould","year":"2012","journal-title":"Neurotherapeutics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fnsyn.2018.00006","article-title":"Purkinje cell signaling deficits in animal models of ataxia.","volume":"10","author":"Hoxha","year":"2018","journal-title":"Front. Synaptic Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.lfs.2009.06.003","article-title":"Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.","volume":"86","author":"Hwang","year":"2010","journal-title":"Life Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S1474-4422(13)70104-2","article-title":"Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data.","volume":"12","author":"Jacobi","year":"2013","journal-title":"Lancet Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/WCO.0b013e32834875ba","article-title":"Update on degenerative ataxias.","volume":"24","author":"Klockgether","year":"2011","journal-title":"Curr. Opin. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/14734220510007950","article-title":"The pathogenesis of spinocerebellar ataxia.","volume":"4","author":"Koeppen","year":"2005","journal-title":"Cerebellum"},{"key":"B26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-3-319-71779-1_11","article-title":"The neuropathology of spinocerebellar ataxia type 3\/Machado-Joseph disease.","volume":"1049","author":"Koeppen","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s12311-013-0456-0","article-title":"The reciprocal cerebellar circuitry in human hereditary ataxia.","volume":"12","author":"Koeppen","year":"2013","journal-title":"Cerebellum"},{"key":"B28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.parkreldis.2016.03.005","article-title":"Safety and efficacy of valproic acid treatment in SCA3\/MJD patients.","volume":"26","author":"Lei","year":"2016","journal-title":"Parkinsonism. Relat. Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease.","volume":"263","author":"L\u00f3pez-Send\u00f3n","year":"2016","journal-title":"J. Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/978-1-4614-0653-2_14","article-title":"Machado-Joseph disease and other rare spinocerebellar ataxias.","volume":"724","author":"Matilla-Due\u00f1as","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-1-4614-0653-2_27","article-title":"The spinocerebellar ataxias: clinical aspects and molecular genetics.","volume":"724","author":"Matilla-Due\u00f1as","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jnc.14541","article-title":"Machado-Joseph disease\/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy.","volume":"148","author":"Matos","year":"2019","journal-title":"J. Neurochem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/brain\/awp292","article-title":"Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3.","volume":"133","author":"Menzies","year":"2010","journal-title":"Brain"},{"key":"B34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","article-title":"Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models.","volume":"7","author":"Moore","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/brain\/awt144","article-title":"Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.","volume":"136","author":"Nascimento-Ferreira","year":"2013","journal-title":"Brain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1083\/jcb.201105092","article-title":"Cell biology of spinocerebellar ataxia.","volume":"197","author":"Orr","year":"2012","journal-title":"J. Cell Biol."},{"key":"B37","first-page":"629","article-title":"Cannabinoid CB1 receptor agonists produce cerebellar dysfunction in mice.","volume":"297","author":"Patel","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/B978-0-444-51892-7.00027-9","article-title":"Machado-Joseph disease\/spinocerebellar ataxia type 3.","volume":"103","author":"Paulson","year":"2012","journal-title":"Handb. Clin. Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrn.2017.92","article-title":"Polyglutamine spinocerebellar ataxias - from genes to potential treatments.","volume":"18","author":"Paulson","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1212\/WNL.0000000000002777","article-title":"Degenerative ataxias, from genes to therapies: the 2015 Cotzias Lecture.","volume":"86","author":"Pulst","year":"2016","journal-title":"Neurology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12311-008-0013-4","article-title":"SCA3: neurological features, pathogenesis and animal models.","volume":"7","author":"Riess","year":"2008","journal-title":"Cerebellum"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/bph.12283","article-title":"Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.","volume":"171","author":"Rodr\u00edguez-Cueto","year":"","journal-title":"Br. J. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000358127","article-title":"Endocannabinoid-hydrolyzing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias.","volume":"81","author":"Rodr\u00edguez-Cueto","year":"","journal-title":"Pathobiology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neuroscience.2016.09.046","article-title":"Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3.","volume":"339","author":"Rodr\u00edguez-Cueto","year":"2016","journal-title":"Neuroscience"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176521","article-title":"Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3.","volume":"12","author":"Rodr\u00edguez-Cueto","year":"2017","journal-title":"PLoS One"},{"key":"B46","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/ene.12350","article-title":"Autosomal dominant cerebellar ataxias: a systematic review of clinical features.","volume":"21","author":"Rossi","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pneurobio.2013.01.001","article-title":"Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7.","volume":"104","author":"R\u00fcb","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1748-1716.2011.02280.x","article-title":"The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.","volume":"204","author":"Savinainen","year":"2012","journal-title":"Acta Physiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-012-1000-x","article-title":"Brain pathology of spinocerebellar ataxias.","volume":"124","author":"Seidel","year":"2012","journal-title":"Acta Neuropathol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/nan.12253","article-title":"Polyglutamine aggregation in Huntington\u2019s disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation.","volume":"42","author":"Seidel","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13311-013-0255-9","article-title":"Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.","volume":"11","author":"Silva-Fernandes","year":"2014","journal-title":"Neurotherapeutics"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.1113\/JP271106","article-title":"Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia?","volume":"594","author":"Stephens","year":"2016","journal-title":"J. Physiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrn1474","article-title":"Pathways to motor incoordination: the inherited ataxias.","volume":"5","author":"Taroni","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.3747\/co.23.3080","article-title":"Anticancer mechanisms of cannabinoids.","volume":"23","author":"Velasco","year":"2016","journal-title":"Curr. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1113\/jphysiol.2012.244947","article-title":"The du(2J) mouse model of ataxia and absence epilepsy has deficient cannabinoid CB1 receptor-mediated signalling.","volume":"591","author":"Wang","year":"2013","journal-title":"J. Physiol."}],"container-title":["Frontiers in Molecular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnmol.2019.00094\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T05:48:39Z","timestamp":1556084919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnmol.2019.00094\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":55,"alternative-id":["10.3389\/fnmol.2019.00094"],"URL":"https:\/\/doi.org\/10.3389\/fnmol.2019.00094","relation":{},"ISSN":["1662-5099"],"issn-type":[{"type":"electronic","value":"1662-5099"}],"subject":[],"published":{"date-parts":[[2019,4,24]]},"article-number":"94"}}